HCCM
REGN icon

Hudson Canyon Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hudson Canyon Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,759
Closed -$2.13M – 55
2026
Q1 		$2.13M Sell
2,759
-15
-0.5% -$11.5K 1.31% 35
2025
Q4 		$2.14M Hold
2,774
– – 1.25% 38
2025
Q3 		$1.78M Buy
2,774
+356
+15% +$201K 1.02% 49
2025
Q2 		$1.27M Hold
2,418
– – 0.79% 52
2025
Q1 		$1.53M Buy
2,418
+99
+4% +$68.1K 1.08% 50
2024
Q4 		$1.65M Hold
2,319
– – 1.08% 45
2024
Q3 		$2.44M Hold
2,319
– – 1.58% 20
2024
Q2 		$2.44M Sell
2,319
-307
-12% -$298K 1.65% 17
2024
Q1 		$2.53M Hold
2,626
– – 1.63% 20
2023
Q4 		$2.31M Sell
2,626
-57
-2% -$46.9K 1.68% 21
2023
Q3 		$2.21M Hold
2,683
– – 1.81% 17
2023
Q2 		$1.93M Sell
2,683
-84
-3% -$64.8K 1.52% 27
2023
Q1 		$2.27M Sell
2,767
-144
-5% -$109K 1.91% 9
2022
Q4 		$2.1M Sell
2,911
-164
-5% -$121K 1.94% 13
2022
Q3 		$2.12M Sell
3,075
-310
-9% -$195K 2.11% 10
2022
Q2 		$2M Sell
3,385
-297
-8% -$193K 1.93% 12
2022
Q1 		$2.57M Hold
3,682
– – 2.03% 11
2021
Q4 		$2.33M Buy
3,682
+196
+6% +$121K 1.69% 20
2021
Q3 		$2.11M Sell
3,486
-127
-4% -$78.8K 1.62% 24
2021
Q2 		$2.02M Sell
3,613
-12
-0.3% -$6.08K 1.51% 32
2021
Q1 		$1.72M Buy
3,625
+275
+8% +$134K 1.35% 43
2020
Q4 		$1.62M Buy
+3,350
New +$1.81M 1.29% 46

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Hudson Canyon Capital Management's REGN Position: Q2 2026 in Review

Hudson Canyon Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 2,759 shares — an estimated $2.13M sold.

Hudson Canyon Capital Management first reported a position in REGN in Q4 2020 and held it in 22 quarters. The position peaked at $2.57M in Q1 2022. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Hudson Canyon Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hudson Canyon Capital Management sold 2,759 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.13M.
  • Hudson Canyon Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 22 quarters.
  • Hudson Canyon Capital Management's Regeneron Pharmaceuticals position peaked at $2.57M in Q1 2022.
  • 1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Hudson Canyon Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.